Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration.
Reversible cerebral vasoconstriction syndrome associated with interferon beta-1a use for multiple sclerosis.
Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study.
Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.
Interferon β for secondary progressive multiple sclerosis: a systematic review.
Santhera and NIH collaborate to evaluate Catena® in primary progressive multiple sclerosis
Launch of a phase 3 clinical trial in the treatment of Alzheimer’s disease with masitinib
Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
Interferon beta for secondary progressive multiple sclerosis.
The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research.
Contribution of the oligodendrocyte lineage to CNS repair and neurodegenerative pathologies.
Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol.
Interferon in relapsing-remitting multiple sclerosis.
Once-daily AUBAGIO® delayed onset of clinically definite multiple sclerosis (MS) in TOPIC study
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.
Raxone®/Catena® (idebenone)
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse-Remitting Multiple Sclerosis
Adaptive autoimmunity and Foxp3-based immunoregulation in zebrafish.
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Genzyme's Lemtrada™ Approved in Brazil for Treatment of Multiple Sclerosis
Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis.
Top ten research priorities for spinal cord injury: the methodology and results of a British priority setting partnership.
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.
Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy.

Pages